We will continue to use market weakness to build positions with decent risk/reward.
Ahead of tomorrow's earnings report, consider taking a profit while leaving protection in place.
The options market is implying about a 3% price move on the report.
Its pharma division outperforms, and our only concern is the stock's high valuation.
Speculation that CEO Jeff Immelt may step down is a step in the right direction.
We could see more squeezes before the correction proceeds on its downward course.
The company is taking meaningful steps to address its recall situation.
Bank of America, Goldman and USB all report this week.
The put will likely expire worthless, but it will cushion any earnings surprises.
The stock is up as the Ukraine crisis lifts oil prices.